Testosterone Topical Gel, 1.62% Metered Pump + AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Primary Hypogonadism
Conditions
Primary Hypogonadism, Hypogonadotropic Hypogonadism
Trial Timeline
Mar 1, 2014 → May 1, 2014
NCT ID
NCT02110368About Testosterone Topical Gel, 1.62% Metered Pump + AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Testosterone Topical Gel, 1.62% Metered Pump + AndroGel (testosterone gel) 1.62% Metered-Dose Pump is a phase 3 stage product being developed by Amneal Pharmaceuticals for Primary Hypogonadism. The current trial status is completed. This product is registered under clinical trial identifier NCT02110368. Target conditions include Primary Hypogonadism, Hypogonadotropic Hypogonadism.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02110368 | Phase 3 | Completed |
Competing Products
20 competing products in Primary Hypogonadism
Other Products from Amneal Pharmaceuticals
CREXONT ERApproved
80
CREXONT ERApproved
80
Diclofenac Sodium Topical Gel, 1% + Voltaren Topical Gel, 1% + Vehicle Diclofenac Sodium Topical GelPhase 3
72
Phenazopyridine Hydrochloride + PlaceboPhase 3
72
Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg + Phenazopyridine Hydrochloride Tables, USP 200 mgPhase 3
72